

Zambia Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia					
2. Grant number: 1821-ZMB-12a-X ; 12-ZMB-08a-Y/ 18-ZMB-25a-Y					
3. Date of Decision Letter: 12 March 2019					
4. Date of the Partnership Framework Agreement: 22 October 2014					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine:					
8. Programme duration¹: 2012 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2012-2018	2019	2020	2021	Total ²
Programme Budget (US\$)	43,173,753 ³	6,689,000	5,244,000	5,220,500	60,327,253
10. Vaccine introduction grant (in US\$) Vaccine introduction grant of US\$207,000 disbursed on 30 January 2012 and US\$ 344,500 on 17 December 2012. Return of unused funds of US\$14,232 on 04 February 2016.					
11. Product switch grant: Country qualifies for a product switch grant of up to US\$ 204,986 to support the PCV switch. The funding will be transferred upon submission and Gavi's approval of the budget for utilisation of the product switch grant. Not applicable					
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2012-2018	2019			
Number of Pneumococcal vaccines doses		1,912,400			
Annual Amounts (US\$)	US\$43,173,753 ⁵	US\$6,689,000			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>									
<p>14. Self-procurement: Not applicable</p>									
<p>15. Co-financing obligations: Reference code: 1821-ZMB-12a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
Type of supplies to be purchased with Country funds in each year	2019	2020	2021						
Number of vaccine doses	393,200	460,000	546,400						
Number of AD syringes	390,200	457,000	543,200						
Number of re-constitution syringes									
Number of safety boxes	4,300	5,050	6,000						
Value of vaccine doses (US\$)	US\$1,198,170	1,262,049	1,499,722						
Total co-financing payments (US\$) (including freight)	US\$1,226,000	US\$1,294,500	US\$1,538,500						
<p>16. Operational support for campaigns: Not applicable</p>									
<p>17. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2019 15 May 2019 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Reports and information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>18. Financial clarifications: Not applicable</p>									

19. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard

Signed by,

Hind A. Khatib

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
12 March 2019